Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
31.10.2025 12:00
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
31.10.2025 12:00
FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti
Is Wall Street Bullish or Bearish on Gilead Sciences Stock?
31.10.2025 09:44
Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.
Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...
31.10.2025 03:00
Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.
Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.
30.10.2025 20:04
Big-name biotech Gilead Sciences issued a mixed third-quarter report late Thursday, with product sales coming in below expectations.
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
30.10.2025 20:01
New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busin
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
29.10.2025 03:13
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.
Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics
27.10.2025 13:15
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
What To Expect From Gilead In Q3 2025
24.10.2025 10:56
Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.
LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
21.10.2025 11:00
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA alone, or as monotherapy in patients unable to tolerate UDCA. This market authorization has been issued with conditions pending the results of trials to verify its clinical benefit.
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
21.10.2025 10:30
WASHINGTON, October 21, 2025--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
13.10.2025 12:30
FOSTER CITY, Calif., October 13, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21.
RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)
03.10.2025 10:28
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc. (NASDAQ:GILD) on September 29 and set a price target of $98.00. Gilead Sciences, Inc. (NASDAQ:GILD) reported a 2% growth in its total revenues for fiscal Q2 2025 to $7.1 […]
Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways
03.10.2025 09:33
Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued stocks to buy and hold for 5 years. On September 25, Gilead Sciences announced that its Gilead Foundation has committed more than $6.5 million in new grant funding to strengthen Science, Technology, Engineering, and Math/STEM education pathways. The funding is part of an ongoing commitment […]
3 Way-Too-Early Predictions For 2026
03.10.2025 08:24
Markets continue to advance despite continuing concerns around valuations, inflation, and the deteriorating jobs market. Read what investors need to know.
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
29.09.2025 12:48
Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for encequidar, a first-in-class P-glycoprotein ("P-gp") inhibitor in the field of virology.
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
29.09.2025 09:45
Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") and Health Hope Pharma ("HHP") granting Gilead the exclusive rights to develop and commercialize encequidar.
Morgan Stanley Maintains Buy on Gilead Sciences (GILD)
29.09.2025 05:39
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 21, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $143. The analyst noted that the US CDC recently recommended the company’s Yeztugo for HIV […]
3 Unpopular Stocks We Approach with Caution
29.09.2025 04:34
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating
26.09.2025 14:48
Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares. While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move […]